|02/26/15||Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibitor Antidote|
|-- Annually, Over 100,000 U.S. Patients Currently Impacted; Projected to Grow Up to 200,000 U.S. Patients by 2020 --
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, has been granted orphan drug designation by the FDA's Office of Orphan Products Development for reversing the anticoagulant effect of direct or indirect Factor Xa inhibi... |
|02/25/15||Portola Pharmaceuticals to Present at the Cowen and Company 35th Annual Health Care Conference|
|SOUTH SAN FRANCISCO, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015 at 8:40 a.m. Eastern Time in Boston.
The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola P... |
|02/24/15||Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2014 Financial Results and Host Conference Call on Monday, March 2|
|SOUTH SAN FRANCISCO, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter and year ended December 31, 2014, and provide a general business overview on Monday, March 2, 2015, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).
Conference Call Details
To access the live conference call, please dial (877) 280-4958 from the U.S. and Canada or +... |
|02/09/15||Portola Pharmaceuticals Appoints Two Biotechnology Industry Veterans, Laura Brege and Dr. Dennis Fenton, to Board of Directors|
|SOUTH SAN FRANCISCO, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of Laura Brege and Dennis Fenton, Ph.D., to its board of directors. Ms. Brege serves as president and chief executive officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Dr. Fenton is the owner and chief executive officer of Fenton and Associates, a biotechnology consulting firm.
"Laura and Dennis have directly relevan... |
|02/05/15||Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis in Phase 3 APEX Study; Trial Continues as Planned and Remains on Track for Enrollment Completion by Year-End|
|Betrixaban Has the Potential to be the First Approved Therapy for Hospital-to-Home Prevention of Fatal Blood Clots for the Over 20 Million High-Risk Acute Medically Ill Patients
SOUTH SAN FRANCISCO, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that the Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study of betrixaban continue as planned withou... |